Media Articles Related to Ortho Micronor (Norethindrone)
The benefits of offering counseling and same-day service to women seeking emergency contraception
Source: Sexual Health / STDs News From Medical News Today [2014.04.08]
Health care clinics should routinely offer same-day placement of intrauterine devices (IUDs) to women seeking emergency contraception, according to researchers at the University of Pittsburgh School...
Published Studies Related to Ortho Micronor (Norethindrone)
Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. [2010.05]
The purpose of this study was to assess effects of colesevelam on the pharmacokinetics of glyburide, levothyroxine, estrogen estradiol (EE), norethindrone (NET), pioglitazone, and repaglinide in healthy volunteers. Six drugs with a potential to interact with colesevelam were studied in open-label, randomized clinical studies.
Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]
BACKGROUND: In postmenopausal women, declining estrogen levels are associated with a variety of skin changes, many of which are reportedly improved by estrogen supplementation. OBJECTIVE: A study was conducted to assess the effects of continuous combined norethindrone acetate (NA) and ethinyl estradiol (EE) in the control of mild to moderate age-related skin changes in postmenopausal women... CONCLUSION: Low-dose hormone therapy for 48 weeks in postmenopausal women did not significantly alter mild to moderate age-related facial skin changes.
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. [2007.09]
OBJECTIVE: This study sought to determine whether combined continuous ethinyl estradiol and norethindrone acetate, a postmenopausal hormone therapy (HT) combination designed to have fewer side effects than cyclical therapies and therapies using medroxyprogesterone acetate (MPA), could improve vascular endothelial function in postmenopausal women with risk factors for cardiovascular disease (CVD)... CONCLUSIONS: In this older postmenopausal population with at least one cardiovascular risk factor, treatment with combined continuous ethinyl estradiol and norethindrone acetate failed to improve vascular endothelial function. The agent's proinflammatory effect or subclinical atherosclerosis in this population may have contributed to this finding.
Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. [2006.11]
CONTEXT: Hormones regulate neuronal function in brain regions critical to cognition; however, the cognitive effects of postmenopausal hormone therapy are controversial. OBJECTIVE: The goal was to evaluate the effect of postmenopausal hormone therapy on neural circuitry involved in spatial working memory... CONCLUSIONS: Hormone therapy was associated with more effective activation of a brain region critical in primary visual working memory tasks. The data suggest a functional plasticity of memory systems in older women that can be altered by hormones.
Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. [2006.06]
BACKGROUND: Based on the potential risks of post-menopausal hormone therapy (HT) found by the Women's Health Initiative, guidelines for HT now recommend use of the lowest effective dose and shortest treatment duration consistent with individual treatment goals. Current (2003) guidance established by the US Food and Drug Administration (FDA) recommends that clinical assessments of HT include women with more frequent and more intense vasomotor symptoms than previously studied. Therefore, this analysis was conducted to further assess the efficacy of a low-dose combination of norethindrone acetate and ethinyl estradiol (NA/EE) previously assessed in dose-ranging studies, while meeting conservative FDA trial design and analysis criteria. OBJECTIVES: The aim of this post hoc analysis and overview was to present data on the efficacy and tolerability of a low-dose combination-NA/EE 0.5 mg/2.5 microg-in the treatment of postmenopausal symptoms, based on data from previously published studies of NA/EE. In addition, the effects of low-dose NA/EE on bone and endometrium are briefly reviewed... CONCLUSIONS: The results from this post hoc analysis and overview of 3 previously published studies suggest that NA/EE 0.5 mg/2.5 microg was associated with decreased frequency and intensity of vasomotor symptoms. This dose of NA/EE was also associated with maintenance of BMD over 24 months, a significant positive effect on BMD compared with placebo. Low-dose NA/EE was also associated with cumulative amenorrhea rates comparable to those of placebo and was not associated with endometrial hyperplasia. This dose was well tolerated, with rates of adverse events generally similar to those of placebo.
Clinical Trials Related to Ortho Micronor (Norethindrone)
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Subjects [Recruiting]
The purpose of this study is to look at how the body processes oral contraceptive (OC),
using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy
female subjects, and the effect of dulaglutide on how Ortho-Cyclen is processed by the body.
Information about any side effects that may occur will also be collected.
Discontinuation of Lens Wear in New Ortho-k Children (DOEE2) [Recruiting]
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada) [Recruiting]
The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho
Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50
years of age who request oral contraceptive protection. Subjects on a LNG, NGM, or
norethindrone/norethindrone acetate containing oral contraceptive in a 21-day regimen
suffering from hormone withdrawal-associated symptoms such of pelvic pain or headache or
both, and willing to continue OC use but to switch to SH T00658ID or Ortho Tri-Cyclen Lo.
Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children [Recruiting]
The primary aim of this study is to compare eyeball elongation in existing ortho-k subjects
who stop the treatment with subjects who continue ortho-k lens wear and control subjects
wearing single-vision glasses.
Drug Interaction - Oral Contraceptive [Completed]
The purpose of this study is to administer a combined oral contraceptive containing ethinyl
estradiol and norgestimate with the HIV treatment of efavirenz to healthy females in order to
assess if the concentrations of the oral contraceptives change. The safety of this treatment
regimen will also be studied.